Literature DB >> 2438285

Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.

G Bepler, G Jaques, A Koehler, C Gropp, K Havemann.   

Abstract

Permanent human small cell lung cancer (SCLC) cell lines established in our laboratory were investigated for their expression of the enzymatic neuroendocrine markers L-DOPA decarboxylase (DDC), neuron-specific enolase (NSE), and creatine kinase (CK), including its BB isoenzyme (CK-BB), the classical tumor markers carcinoembryonic antigen (CEA), the alpha and beta subunits of human chorionic gonadotropin (alpha-HCG, beta-HCG), and alpha-fetoprotein (alpha-FP), and their chromosomal characteristics. DDC activities were detectable in 5/6 SCLC cell lines and absent in non-SCLC. NSE levels ranged from 160 to 1422 ng/mg soluble protein and were less than 290 ng/mg soluble protein in non-SCLC. Activities of CK and levels of CK-BB clearly distinguished SCLC from non-SCLC with CK activities greater than 1000 munits/mg soluble protein and CK-BB levels greater than 3000 ng/mg soluble protein in SCLC and less than 300 munits/mg soluble protein and less than 2000 ng/mg soluble protein in non-SCLC. CEA was detectable in 5/6 SCLC cell lines but absent in non-SCLC, and its level seemed to correlate with those of DDC, NSE, and CK. One cell line, SCLC-16H, lost some of its neuroendocrine properties and CEA after 1 year of in vitro cultivation. Generally, marker levels were low in fast growing cell lines and high in slow growing cell lines. HCG alpha and beta subunit and alpha-FP were not detectable in SCLC cell lines. All SCLC cell lines examined had near diploid DNA indices and modal chromosome numbers. Double minute chromosomes and homogeneously staining regions were found in 2/5 and 4/5 SCLC cell lines respectively. With respect to chromosomal aberrations, we found a deletion of the short arm of at least one chromosome 3 in all SCLC cell lines (5/5). These data show that SCLC expresses neuroendocrine markers and CEA; CK is the most sensitive marker, and DDC and CEA are the most specific markers for SCLC in vitro; individual marker levels correlate with each other and the in vitro malignancy of SCLC; and SCLC cell lines have relatively uniform chromosomal characteristics. Our results suggest that patients whose tumors have high levels of DDC, NSE, CK-BB, and CEA have a better prognosis than those with low marker levels. This hypothesis could be proved by comparing pairs of patients that are matched for all known prognostic parameters, in particular tumor spread, for their serum and tumor marker levels with respect to the patients' outcome and prognosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438285     DOI: 10.1007/bf00396382

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Expression of peptide and other markers in lung cancer cell lines.

Authors:  A F Gazdar; D N Carney; K L Becker; L J Deftos; V Liang; W Go; P J Marangos; T W Moody; A R Wolfsen; M H Zweig
Journal:  Recent Results Cancer Res       Date:  1985

2.  Elevated serum creatine kinase BB levels in patients with small cell lung cancer.

Authors:  D N Carney; M H Zweig; D C Ihde; M H Cohen; R W Makuch; A F Gazdar
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

3.  Immunocytochemical staining for CEA in small cell carcinoma of lung predicts clinical usefulness of the plasma assay.

Authors:  R H Goslin; M J O'Brien; A T Skarin; N Zamcheck
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

4.  Association of diamine oxidase and ornithine decarboxylase with maturing cells in rapidly proliferating epithelium.

Authors:  S B Baylin; S A Stevens; K M Shakir
Journal:  Biochim Biophys Acta       Date:  1978-07-03

5.  Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment.

Authors:  T P Waalkes; M D Abeloff; K B Woo; D S Ettinger; R W Ruddon; P Aldenderfer
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

6.  Epitopes of carcinoembryonic antigen defined by monoclonal antibodies prepared from mice immunized with purified carcinoembryonic antigen or HCT-8R cells.

Authors:  A Haggarty; C Legler; M J Krantz; A Fuks
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

7.  Establishment and characterization of a continuous lung squamous cell carcinoma cell line (U-1752).

Authors:  J Bergh; K Nilsson; L Zech; B Giovanella
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

8.  Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23).

Authors:  J Whang-Peng; C S Kao-Shan; E C Lee; P A Bunn; D N Carney; A F Gazdar; J D Minna
Journal:  Science       Date:  1982-01-08       Impact factor: 47.728

9.  Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung.

Authors:  J Bergh; K Nilsson; R Ekman; B Giovanella
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1985-05

10.  Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung.

Authors:  O S Pettengill; G D Sorenson; D H Wurster-Hill; T J Curphey; W W Noll; C C Cate; L H Maurer
Journal:  Cancer       Date:  1980-03-01       Impact factor: 6.860

View more
  11 in total

1.  Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.

Authors:  L Hermitte; N Martin-Moutot; J Boucraut; R Barone; C Atlan-Gepner; M Seagar; J Pouget; J P Kleisbauer; F Couraud; B Vialettes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

3.  Immunotargeting of human small cell lung cancer xenografts in athymic mice using a monoclonal antibody (RNL-1) against a neuroendocrine-related antigen.

Authors:  E P Mijnheere; O C Boerman; J L Broers; M Klein Rot; G P Vooijs; F C Ramaekers
Journal:  Br J Cancer Suppl       Date:  1991-06

4.  Release of membrane-associated L-dopa decarboxylase from human cells.

Authors:  Ioanna Chalatsa; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Neurochem Res       Date:  2011-04-11       Impact factor: 3.996

5.  Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.

Authors:  H H Heidtmann; U Salge; M Abrahamson; M Bencina; L Kastelic; N Kopitar-Jerala; V Turk; T T Lah
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

6.  Tetanus toxin as a marker for small-cell lung cancer cell lines.

Authors:  J Heymanns; K Neumann; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

7.  Reliability of commercially available immunocytochemical markers for identification of neuroendocrine differentiation in bronchoscopic biopsies of bronchial carcinoma.

Authors:  J R Gosney; M A Gosney; M Lye; S A Butt
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

8.  Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects.

Authors:  G Bepler; M Rotsch; G Jaques; M Haeder; J Heymanns; G Hartogh; P Kiefer; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Synaptophysin: molecular organization and mRNA expression as determined from cloned cDNA.

Authors:  R E Leube; P Kaiser; A Seiter; R Zimbelmann; W W Franke; H Rehm; P Knaus; P Prior; H Betz; H Reinke
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

10.  Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.

Authors:  R Schwartz-Albiez; H H Heidtmann; D Wolf; V Schirrmacher; G Moldenhauer
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.